DARA BioSciences (Nasdaq: DARA) on Monday began selling a liquid version of the breast cancer drug tamoxifen for patients who have difficulty swallowing pills.
The liquid version is called Soltamox.
It is available by prescription.
“Soltamox may offer patients who need tamoxifen therapy an important treatment option,” DARA said.
In its announcement DARA pointed out: “According to a 2011 study published in The Lancet, a five-year course of tamoxifen treatment in women with estrogen-receptor-positive breast cancer cut their risk of death by about one-third over a 15-year period. Unfortunately, for some people with breast cancer, the pill form of tamoxifen can be difficult to swallow due to a variety of reasons, including the effects of radiation, surgery and chemotherapy. Some people simply prefer liquid medications over pills or hope to reduce the number of pills they need to take on a daily basis.”
